Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Phase I Study to Evaluate the Effect of Ofatumumab on Cardiac Repolarization (QTc Duration) in Patients With Fludarabine-Refractory B-cell Chronic Lymphocytic Leukemia

NCT01110031 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01110031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01110031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Phase I Study to Evaluate the Effect of Ofatumumab on Cardiac Repolarization (QTc Duration) in Patients With Fludarabine-Refractory B-cell Chronic Lymphocytic Leukemia
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
May 13, 2010
Completion date
June 26, 2012
Enrollment
12 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

leukaemia, lymphocytic, chronic